Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452268 · ClinicalTrials.gov registry record · Phase 1
A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT02452268 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 83 participants.
The verdict
NCT02452268, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion
Interventions
- DRUG PDR001
- DRUG NIZ985
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2022-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452268
The ClinicalTrials.gov registry entry for NCT02452268 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT02452268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02452268 about?
NCT02452268 is a clinical study titled "A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers". Phase I/Ib multicenter clinical trial. Single agent dose escalation of NIZ985 followed by expansion. Second escalation of NIZ985 in combination with PDR001 followed by expansion
What is the current status of trial NCT02452268?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2017-05-08. Estimated completion is 2022-03-07.
What interventions are being tested in trial NCT02452268?
The interventions under investigation include: PDR001 (DRUG), NIZ985 (DRUG).
Who is sponsoring clinical trial NCT02452268?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.